These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11593896)

  • 1. [Endocrine orbitopathy--diagnosis].
    Langmann A; Lindner S
    Acta Med Austriaca; 2001; 28(4):87-8. PubMed ID: 11593896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical signs of dysthyroid orbitopathy].
    Camezind P; Robert PY; Adenis JP
    J Fr Ophtalmol; 2004 Sep; 27(7):810-4. PubMed ID: 15499282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some important ophthalmological aspects of endocrine orbitopathy.
    Goder GJ
    Radiobiol Radiother (Berl); 1987; 28(5):539-41. PubMed ID: 3441596
    [No Abstract]   [Full Text] [Related]  

  • 4. [A clinical analysis of Graves' ophthalmopathy and ophthalmic Graves' disease].
    Liao ZQ
    Zhonghua Yan Ke Za Zhi; 1992 Jul; 28(4):236-9. PubMed ID: 1299571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clever is not enough: NOSPECS is form in search of function.
    Gorman CA
    Thyroid; 1991; 1(4):353-5. PubMed ID: 1841733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interdisciplinary diagnosis and treatment of endocrine orbitopathy (Graves' disease) (author's transl)].
    Wulle KG; Brunk G; Utech C; Pfannenstiel P
    Klin Monbl Augenheilkd; 1980 Nov; 177(5):551-5. PubMed ID: 6894774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raising awareness of Graves' orbitopathy with early warning cards.
    Mitchell AL; Hickey J; Vaidya B; Mason R; Ajjan R; Zammitt N; Perros P; Dayan C;
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):853-859. PubMed ID: 28755510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease.
    Frueh BR
    Thyroid; 1992; 2(1):85-8. PubMed ID: 1525574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease.
    Burggasser G; Hurtl I; Hauff W; Lukas J; Greifeneder M; Heydari B; Thaler A; Wedrich A; Virgolini I
    J Nucl Med; 2003 Oct; 44(10):1547-55. PubMed ID: 14530465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of graves' orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves' disease.
    Mourits MP
    Orbit; 2008; 27(6):399-400. PubMed ID: 19085291
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term results of surgical treatment in Graves' disease orbitopathy. Is there a correlation between the extent of thyroidectomy and the course of orbithopathy?
    Maurer E; Dănilă R; Dominguez E; Osei-Agymang T; Zielke A; Hassan I
    Chirurgia (Bucur); 2008; 103(3):291-5. PubMed ID: 18717277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
    Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
    Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graves' ophthalmopathy. A clinical and immunologic review.
    Sergott RC; Glaser JS
    Surv Ophthalmol; 1981; 26(1):1-21. PubMed ID: 6895125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Graves' orbitopathy and its results. A retrospective analysis.
    Kahaly G; Böckmann H; Beyer J; Cordes U
    Dev Ophthalmol; 1989; 20():109-26. PubMed ID: 2687047
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultrasonic B-scan measurement of the extra-ocular muscles in Graves' orbitopathy.
    Willinsky RA; Arenson AM; Hurwitz JJ; Szalai J
    J Can Assoc Radiol; 1984 Jun; 35(2):171-3. PubMed ID: 6384227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Graves' ophthalmopathy--a prospective clinical study].
    Bogdănici C; Marcu C
    Oftalmologia; 1999; 48(3):19-22, 25. PubMed ID: 10641113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New perspectives for the diagnosis and prognosis of Graves' disease].
    Tatulashvili S; Baudry C; Sadoul JL; Bihan H
    Ann Endocrinol (Paris); 2018 Sep; 79 Suppl 1():S31-S39. PubMed ID: 30213303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.